{
    "organizations": [],
    "uuid": "b0514600378ee8fc4c747f547a4df003173f6da3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-hemispherx-provides-an-update-to-s/brief-hemispherx-provides-an-update-to-stockholders-highlighting-cancer-focus-idUSASC09YZY",
    "ord_in_thread": 0,
    "title": "BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2, 2018 / 12:48 PM / Updated 13 minutes ago BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus Reuters Staff 1 Min Read\nMay 2 (Reuters) - Hemispherx Biopharma Inc:\n* HEMISPHERX PROVIDES AN UPDATE TO STOCKHOLDERS HIGHLIGHTING CANCER FOCUS AND $10 MILLION BOOKED SINCE START OF YEAR WILL SUPPORT INCREASED PRODUCTION OF AMPLIGEN FOR IMMUNO-ONCOLOGY CLINICAL TRIALS Source text for Eikon: Further company coverage:",
    "published": "2018-05-02T15:46:00.000+03:00",
    "crawled": "2018-05-02T16:03:28.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "provides",
        "update",
        "stockholder",
        "highlighting",
        "cancer",
        "focus",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "hemispherx",
        "biopharma",
        "inc",
        "hemispherx",
        "provides",
        "update",
        "stockholder",
        "highlighting",
        "cancer",
        "focus",
        "million",
        "booked",
        "since",
        "start",
        "year",
        "support",
        "increased",
        "production",
        "ampligen",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}